Evidence map›Paper›PMID 27906679›Full record

SynthesisOncotarget2017

Platelet-lymphocyte ratio acts as an indicator of poor prognosis in patients with breast cancer.

Yanyun Zhu, Wen Si, Qiong Sun, Boyu Qin, Weihong Zhao, Junlan Yang

Abstract readMeta-Analysis
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Oncotarget, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 48 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
48citing papers in PubMed, 6 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

48 citing papers in PubMed, 6 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Trial
  8. Article
  9. Article
  10. Platelet Indices as a Biomarker in Distinguishing Benign and Malignant Breast Lesions.Asian Pacific journal of cancer prevention : APJCP · 2026
    Article
  11. Observational
  12. Observational
  13. Article
  14. Review
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Yanyun ZhuDepartment of Medical Oncology, Chinese PLA General Hospital, Beijing 100853, China.
Wen SiDepartment of Medical Oncology, Beijing Shijitan Hospital, Capital Medical University, Beijing 100038, China.
Qiong SunDepartment of Medical Oncology, Chinese PLA General Hospital, Beijing 100853, China.
Boyu QinDepartment of Medical Oncology, Chinese PLA General Hospital, Beijing 100853, China.
Weihong ZhaoDepartment of Medical Oncology, Chinese PLA General Hospital, Beijing 100853, China.
Junlan YangDepartment of Medical Oncology, Chinese PLA General Hospital, Beijing 100853, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Platelet-lymphocyte ratio (PLR) is a hematological parameter which is investigated as a biomarker for prognosis in patients with breast cancer. Due to the controversial results from previous studies, we performed a meta-analysis. Databases of PubMed, Embase and Web of Science were searched to identify eligible studies. STATA version 12.0 was used for statistical analysis. Seven studies with 3,741 patients were ultimately included in this meta-analysis. High PLR was associated with poor overall survival (OS) (HR = 1.55, 95% CI = 1.07-2.25, p = 0.022) and disease-free survival (DFS) (HR = 1.73, 95% CI = 1.3-2.3, p < 0.001) in breast cancer patients. Subgroup analyses disclosed that elevated PLR could predict worse OS in Asian populations and poor DFS in both Asian and non-Asian patients. In addition, PLR remains a significant prognostic marker for OS in patients receiving systemic treatment (HR = 1.78, 95% CI = 1.06-2.99, p = 0.03) and patients receiving chemotherapy (HR = 2.82, 95% CI = 1.09-7.26, p = 0.032). High PLR also indicates poor DFS in patients who receive chemotherapy (HR = 2.6, 95% CI = 1.47-4.61, p = 0.001), surgery (HR = 1.8, 95% CI = 1.12-2.89, p = 0.016) and systemic treatment (HR = 2.03, 95% CI = 1.03-4.01, p = 0.042). Moreover, PLR was also in association with HER-2 positivity (OR = 1.48, 95% CI = 1.2-1.83, p < 0.001). In conclusion, this meta-analysis revealed that PLR could serve as an indicator of poor prognosis in patients with breast cancer.

Indexed as

Blood PlateletsLymphocyte CountLymphocytesPlatelet CountBiomarkersBreast NeoplasmsFemaleHumansNeoplasm GradingNeoplasm MetastasisNeoplasm StagingPrognosisPublication BiasBiomarkersbiomarkerbreast cancermeta-analysisPLRprognosis

Identifiers

PMID27906679
PMCPMC5352031

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.